Federal health officials held an unannounced, closed-door demo day with ten clinical-AI companies at FDA headquarters. The episode captures a real tension, regulators need to understand fast-moving technology firsthand, but private, selective access is the classic setup for regulatory capture.
The Senate confirmed Dr. Erica Schwartz to lead the CDC after she declined to say whether she would defend the agency's science against political pressure. That evasiveness was not a flaw in her candidacy, it was the mechanism that made her confirmable.
A new analysis finds that exempting orphan drugs from Medicare's drug-pricing pilots would erase most of their savings. The paradox unwinds once you see that the orphan label, meant for tiny markets, now also covers blockbusters like Keytruda.
Prostate cancer is extremely common and rarely deadly, a combination partly explained by overdiagnosis. Growing trial evidence favors MRI-first diagnosis over systematic biopsy precisely because it finds less indolent cancer, not more.
At a Chicago conference of Black financial professionals, Ariel Investments' John Rogers and other advisors laid out three kinds of social capital that build a career, internal, community, and mentorship. All three compound through the same counterintuitive rule, they are built by giving, not by extracting.
Compass guided to roughly double last year's revenue after acquiring Anywhere Real Estate for $1.6 billion. Most of that doubling is merger arithmetic, not growth, and the earnings that actually matter are a test of whether the integration is working.
Nearly 200 private colleges drew on restricted donor endowments in 2025, mostly for operating expenses rather than the purposes donors specified. A restricted gift is a legally binding promise, not a reserve, and the real wrong is usually not redeployment but doing it without consent.
A strong El Niño is confirmed and building, and the conventional playbook says buy fertilizer, sell food processors, trade the crop spikes. A knowable weather event is precisely the kind that's hardest to profit from, because everyone already knows about it.
Yellow.ai is going public via SPAC with a plan to acquire business-process outsourcing firms and automate them rather than sell software to them. The inversion of the normal software playbook is a sharp bet about where AI's value gets captured in a labor-heavy services market, and a genuinely risky one.
Federal agencies say essential disease monitoring remains intact. Specialists warn that reduced staffing could make emerging threats harder to detect.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.